Trial Profile
A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Fibromyalgia; Insomnia
- Focus Therapeutic Use
- 08 Aug 2018 Status changed from recruiting to discontinued.
- 21 Feb 2018 Planned End Date changed from 1 Sep 2017 to 30 Sep 2018.
- 21 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2018.